Delegation Guide for Pharma CEO Regulatory Strategy

Regulatory strategy is the function that most directly determines the pace of drug approval, the scope of an approved label, and the long-term commercial viability of a pharmaceutical product. No function in a pharmaceutical company has more concentrated impact on enterprise value. Yet regulatory strategy is also one of the most specialized functions in the industry - requiring deep expertise in FDA science, regulatory precedent, agency relationships, and the evolving landscape of expedited development programs.

This creates a distinctive delegation challenge for pharma CEOs. Regulatory strategy is too important to ignore and too specialized to personally manage. The CEO must set the strategic context, make decisions at major inflection points, and maintain high-level agency relationships - while delegating all operational regulatory activities to expert regulatory affairs leadership.

Why Regulatory Strategy Delegation Is Distinctively Challenging

Unlike commercial operations or manufacturing, where the CEO can monitor performance through financial and operational metrics, regulatory strategy is often driven by judgment calls on uncertain scientific and policy questions. Whether to pursue an accelerated approval pathway, how to design a pivotal trial to support a broad label, when to request a breakthrough therapy designation - these decisions require scientific and regulatory expertise that most pharma CEOs do not personally possess.

This expertise gap creates a temptation to either over-delegate (treating regulatory strategy as purely technical and ignoring it) or under-delegate (relying on regulatory affairs leaders for technical analysis but making final decisions based on insufficient understanding). Neither approach serves the organization.

Effective regulatory delegation requires CEOs to invest in understanding the strategic implications of regulatory decisions - not the technical details, but the clinical, commercial, and organizational consequences of different regulatory strategies - so they can make informed decisions at the right level.

McKinsey research on pharmaceutical leadership emphasizes that the most effective pharma CEOs develop working knowledge of the regulatory landscape in their therapeutic areas - not to replace their regulatory affairs experts, but to engage with regulatory strategy decisions with sufficient sophistication to ask the right questions.

The CEO’s Non-Delegable Regulatory Functions

Regulatory pathway decisions with major commercial implications. The decision to pursue accelerated approval versus traditional approval, to seek a broad indication versus a narrow biomarker-defined label, or to file for approval in a lead market versus simultaneous global submissions has profound commercial and scientific consequences. These decisions require CEO input and final authority.

FDA relationship at the senior leadership level. While the Chief Regulatory Officer manages the operational FDA relationship, the CEO should have personal relationships with the heads of the FDA centers relevant to the company’s programs (CDER for small molecules and most biologics, CBER for gene therapies and cell therapies, CDRH for combination products). These relationships are not operational but strategic - enabling direct dialogue about agency priorities and providing context for regulatory interactions.

Adverse regulatory outcomes. When a complete response letter, refusal to file, or clinical hold occurs, the CEO must be directly involved in the strategic response. These events affect company value, investor confidence, and patient access to potentially important medicines.

External communication about regulatory milestones. Regulatory approvals, PDUFA dates, advisory committee meeting outcomes, and significant regulatory setbacks require CEO-level communication to investors and the public.

Board regulatory reporting. The CEO is responsible for ensuring the board receives appropriate regulatory risk visibility. The CEO synthesizes regulatory risk information for the board, with input from the CRO.

What Should Be Delegated to Regulatory Affairs Leadership

The vast majority of regulatory work should be fully owned by the regulatory affairs organization. This includes:

Development phase regulatory work:

• IND preparation and maintenance
• Pre-IND and Type B meeting request preparation
• Pediatric Study Plan preparation
• Fast track, breakthrough therapy, orphan drug, and other designation requests
• Protocol development consultation with FDA
• Special Protocol Assessment requests

Approval phase regulatory work:

• NDA, BLA, ANDA, or sNDA preparation and submission
• Type A meeting preparation and management
• Advisory committee preparation, mock panel facilitation, and hearing logistics
• Label negotiation strategy and execution (with CEO review of contentious label language)
• Post-approval commitment management

Operational regulatory work:

• Annual IND reporting
• Manufacturing change submissions
• Labeling updates
• International regulatory filing management
• Regulatory intelligence monitoring and dissemination

To whom: Chief Regulatory Officer or VP of Regulatory Affairs, supported by regulatory directors for each product program and a regulatory intelligence/strategy function.

The pharma CEO guide provides a comprehensive framework for how regulatory delegation fits within the overall pharma enterprise governance model.

Building an Effective Regulatory Affairs Organization

Delegation of regulatory strategy is only possible when the regulatory affairs organization is led by a CRO with the depth of experience and organizational authority to make decisions independently. The characteristics of a CRO capable of absorbing CEO-level regulatory delegation include:

Deep therapeutic area expertise. The CRO should have experience with the FDA offices and review divisions relevant to the company’s programs. A CRO who has navigated similar regulatory pathways - breakthrough therapy interactions, accelerated approval, advisory committees - brings judgment that purely generalist regulatory background cannot provide.

Strong FDA relationships. The CRO should have developed personal relationships with senior FDA reviewers and division directors over the course of their career. These relationships facilitate productive regulatory interactions and help the organization navigate ambiguous situations.

Strategic thinking alongside regulatory expertise. The CRO must be capable of synthesizing regulatory options into strategic recommendations for the CEO, not just presenting regulatory options neutrally. The CEO needs actionable guidance from regulatory leadership, not regulatory encyclopedias.

Organizational authority. The CRO must have genuine authority to make regulatory decisions within defined parameters. A CRO who must escalate every substantive regulatory question to the CEO is not capable of managing the regulatory function at the required level.

The CEO-CRO Interface

The CEO-CRO relationship is one of the most important in a pharmaceutical company. Several practices make this interface productive:

Regular briefings. A standing 30-minute weekly briefing from the CRO keeps the CEO informed of upcoming regulatory interactions, emerging regulatory risks, and significant developments without pulling the CEO into operational details.

Decision-level clarity. The CEO and CRO should maintain a shared understanding of which regulatory decisions require CEO input (major pathway decisions, contentious label disputes, adverse regulatory actions) and which the CRO owns (all operational regulatory activities, routine FDA interactions, label negotiation within agreed parameters).

Regulatory scenario planning. For each major regulatory milestone, the CRO prepares a scenario analysis covering expected outcomes, alternative outcomes, and the strategic implications of each. The CEO reviews the scenario analysis before major FDA interactions, ensuring informed oversight without requiring technical regulatory expertise.

Honest escalation culture. The CRO must be willing to escalate bad news quickly - unexpected FDA requests, delayed review timelines, negative advisory committee signals - without filtering or softening. A culture where regulatory setbacks are escalated immediately and without fear enables the CEO to respond strategically rather than reactively.

Regulatory Strategy During Business Development

When the company is engaged in licensing in or licensing out of programs, regulatory strategy is a key element of business development diligence. The CRO should lead regulatory due diligence for incoming programs and provide regulatory representation in outbound licensing discussions.

What to delegate:

• Regulatory due diligence for in-licensing candidates
• Regulatory representation in licensing and partnership negotiations
• Preparation of regulatory assessments for term sheet development

What the CEO retains: Final deal decisions that are influenced by regulatory strategy assessment, and representation in partnership discussions where regulatory commitments are a major negotiated element.

For context on how regulatory strategy fits within the broader business development delegation framework for biotech and pharma companies, the pharma product launch guide covers how regulatory readiness is integrated with commercial launch planning.

International Regulatory Delegation

Global pharmaceutical companies must manage regulatory submissions and relationships across multiple jurisdictions. The organizational model for international regulatory management should be clearly defined.

What to delegate:

• EMA submission strategy and management
• Health Canada, TGA, MHRA, and other major agency submission management
• International regulatory intelligence
• Harmonization and reliance strategy for international submissions

To whom: VP of International Regulatory Affairs or the CRO, depending on organizational scale.

What the CEO retains: Decisions about which markets to prioritize for international regulatory submissions, particularly when competing resource demands require prioritization choices.

Common Regulatory Delegation Failures

CEO advisory committee attendance. Some pharma CEOs feel compelled to attend every FDA advisory committee meeting related to their products. This is usually not the appropriate CEO role - advisory committees are scientific and technical forums best managed by the CMO and CRO. The CEO should be informed of advisory committee outcomes and prepared to communicate externally about them, but should not typically participate in the advisory committee process itself.

Label language micromanagement. CEOs who personally review and revise label language are operating at a level of detail that belongs to the regulatory and medical affairs teams. The CEO should review and approve strategic label decisions (breadth of indication, key contraindications, boxed warning acceptance or rejection) but should not be involved in the language of specific label sections.

Regulatory intelligence overload. CEOs who subscribe to detailed regulatory intelligence feeds and attempt to personally track FDA guidances and policy developments are misusing their bandwidth. The regulatory affairs organization should synthesize regulatory intelligence and bring relevant strategic implications to the CEO’s attention.

Conclusion

Regulatory strategy sits at the heart of pharmaceutical value creation. It determines what products reach patients, when they reach them, and with what label. It is too important to ignore and too specialized to personally manage at the operational level.

Pharma CEOs who delegate regulatory operations to expert CROs with genuine authority - while maintaining strategic engagement on pathway decisions, FDA senior leadership relationships, and adverse outcome responses - create the regulatory governance model that best serves patients, investors, and the organization’s mission.

Related Reading

For further context, explore Delegation Guide for Affordable Housing Nonprofit CEOs and Delegation Guide for Automotive CEO: Brand Management.